Consensus IntelGenx Technologies Corp.

Equities

IGXT

US45822R1014

Market Closed - OTC Markets Other stock markets 01:29:28 04/05/2024 am IST			5-day change	1st Jan Change
0.179 ^USD	+0.28%		+9.15%	+29.62%

08/04	Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	CI
05/04	IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	MT

Evolution of the average Target Price on IntelGenx Technologies Corp.

Price target over the last 5 years

History of analyst recommendation changes

6e58eb3a40020f393b033.NNbQWM5e0dP0xscwO0JdoVS-0WtzvfnnCpJ7xosg60g.RYmHDoMvnLvFoJFcCwYl1i3LoF8hzLiBb80Nssp5nHBYvKRvgjm9h5as_w~7bf0232fde66b3cd013547a96aedd6c7

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1619

Average target price